Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.

Authors:
Celum C; Grinsztejn B; Ngure K.

Journal:
J Int AIDS Soc

Publication Year: 2023

DOI:
10.1002/jia2.26103

PMCID:
PMC10339005

PMID:
37439077

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Int AIDS Soc

Abbreviation: J Int AIDS Soc

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Acquired Immunodeficiency Syndrome

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Advanced disease programming brings much needed attention and improvements to inpatient paediatric …
Buck WC; Schindele A; Taibo E and 6 more (2024) - Transparency Score: 3/6
HIV pre-exposure prophylaxis programme preferences among sexually active HIV-negative transgender a…
Watson DL; Listerud L; Drab RA and 3 more (2024) - Transparency Score: 3/6
Integrating methadone into primary care settings in Ukraine: effects on provider stigma and knowled…
Bromberg DJ; Machavariani E; Madden LM and 8 more (2024) - Transparency Score: 3/6
Long-term retention on antiretroviral treatment after enrolment in prevention of vertical HIV trans…
Urrio RF; Lyatuu GW; Sando D and 14 more (2024) - Transparency Score: 3/6
My Way: development and preliminary evaluation of a novel delivery system for PrEP and other sexual…
Haberer JE; Oware K; Juma L and 9 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"COMPETING INTERESTS CC has received research grants from NIH, USAID, and Bill and Melinda Gates Foundation, has served on the advisory board for Gilead Sciences and Merck, and has served as an expert witness for Gilead. BG has served on advisory boards for Janssen, GlaxoSmithKline and Merck. KN has received research grants from NIH, Bill and Melinda Gates Foundation, and Merck."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025